Search clinical trials for: Cixutumumab

Total 46 results

Eli Lilly and Company

Completed

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

Adenocarcinoma of the Prostate

United States
National Cancer Institute (NCI)

Completed

Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy

Peritoneal Mesothelioma | Pleural Mesothelioma

United States
Eli Lilly and Company

Completed

A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

Leiomyosarcoma | Rhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET) | Adipocytic Sarcoma

United States, Germany, Poland, Belgium, Spain, France, Netherlands
Eli Lilly and Company

Completed

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Head and Neck Cancer

United States
Eli Lilly and Company
Parexel; Medidata Solutions

Completed

A Study of IMC-A12 in Advanced Solid Tumors

Tumors

Japan
Eli Lilly and Company

Completed

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

Hepatocellular Carcinoma

United States
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Daiichi Sankyo

Not yet recruiting

A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer)

Brain Metastases, Adult

United States
University of Manchester
Lancaster University

Completed

Physiological Effects of Stevia Consumption in Humans

Obesity | Glucose Intolerance

United Kingdom
Eli Lilly and Company

Completed

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

Colorectal Cancer

United States
Eli Lilly and Company
NSABP Foundation Inc

Terminated

A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab (FC-4)

Rectal Cancer | Colon Cancer

United States
Eli Lilly and Company

Completed

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

Advanced Solid Tumors

United States
Eli Lilly and Company

Completed

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

Advanced Solid Tumors

United States
Eli Lilly and Company

Completed

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Non-Small Cell Lung Cancer

United States
Eli Lilly and Company

Completed

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Carcinoma | Neuroendocrine Tumors

United States
National Cancer Institute (NCI)

Completed

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma

United States
Eli Lilly and Company

Completed

A Study in Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

Argentina, Israel, United States, Spain, Germany, Belgium, Italy, Brazil, France, Canada, Netherlands, Turkey
National Cancer Institute (NCI)

Completed

IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor

Unspecified Childhood Solid Tumor, Protocol Specific | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

United States
Eli Lilly and Company

Completed

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Metastatic Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Wilms Tumor and Other Childhood Kidney Tumors | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Neuroectodermal Tumor and other conditions

United States, Canada, Australia
University of Washington

Completed

Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

Adult Solid Neoplasm

United States
National Cancer Institute (NCI)

Terminated

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

Recurrent Adrenocortical Carcinoma | Stage III Adrenocortical Carcinoma | Stage IV Adrenocortical Carcinoma

United States
National Cancer Institute (NCI)

Completed

IMC-A12 in Treating Patients With Advanced Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
University of Brasilia
Ministry of Health, Brazil

Completed

Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children (LVTO)

Visceral Leishmaniasis

Brazil
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

Unspecified Childhood Solid Tumor, Protocol Specific

United States, Canada
National Cancer Institute (NCI)

Terminated

Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Large Cell Lung Carcinoma | Bronchioloalveolar Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

Malignant Neoplasm

United States
National Cancer Institute (NCI)
Southwest Oncology Group

Completed

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Recurrent Breast Carcinoma | HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
Astellas Pharma Global Development, Inc.

Terminated

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis (MAGIC-2)

Candidiasis

Philippines, United States, Canada, Israel, Romania, Greece, Turkey, Brazil, Bulgaria, Colombia, Hungary, Ukraine
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7

United States
National Cancer Institute (NCI)

Completed

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Stage IV Pancreatic Cancer

United States
M.D. Anderson Cancer Center
Eli Lilly and Company; Genentech, Inc.

Completed

BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

Rhabdomyosarcoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Childhood Angiosarcoma | Childhood Epithelioid Sarcoma | Childhood... and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Recurrent Osteosarcoma | Metastatic Osteosarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States, Canada
Eli Lilly and Company

Completed

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Lung Carcinoid Tumor | Metastatic Digestive System Neuroendocrine Tumor G1 | Paraganglioma | Pancreatic Polypeptide Tumor | Pancreatic Glucagonoma | Pancreatic Insulinoma | Recurrent Merkel Cell Carcinoma | Somatostatin-Producing Neuroendocrine Tumor | Stage IV Merkel Cell Carcinoma | Recurrent Digestive... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Dermatofibrosarcoma Protuberans | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Adult Angiosarcoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer

United States, Canada
National Institute of Diabetes and Digestive and...

Recruiting

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

Healthy Volunteers

United States
National Cancer Institute (NCI)

Completed

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage

Extensive Stage Small Cell Lung Carcinoma | Recurrent Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Stage IV Adult Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Childhood Alveolar Rhabdomyosarcoma | Childhood Embryonal Rhabdomyosarcoma | Untreated Childhood Rhabdomyosarcoma

United States, Canada, Australia, New Zealand

Search clinical trials for: Cixutumumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations